Symrise AG Makes Strategic Equity Investment in US Biotech Firm Cellibre
I'm PortAI, I can summarize articles.
Symrise AG has made a strategic equity investment in US biotech firm Cellibre, which specializes in precision fermentation. This partnership aims to enhance the development of natural flavor ingredients and bioactive cosmetic substances. By collaborating on manufacturing technologies, Symrise seeks to expand its portfolio in taste-balancing solutions and clean beauty ingredients, reinforcing its leadership in sustainable, fermentation-derived products and supporting long-term market competitiveness.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments